<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550119</url>
  </required_header>
  <id_info>
    <org_study_id>3C-06-1</org_study_id>
    <secondary_id>NCI-2012-01740</secondary_id>
    <secondary_id>3C-06-1</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT02550119</nct_id>
  </id_info>
  <brief_title>Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination With Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-containing Regimen Which Includes 5-FU.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without
      aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing
      chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent
      nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving
      aprepitant together with dolasetron mesylate and dexamethasone is more effective than
      dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the incidence and severity of acute and delayed nausea and vomiting associated
      with oxaliplatin-containing regimens in patients with gastrointestinal (GI) malignancy.

      II. To estimate the percent of patients who have experienced nausea and vomiting with their
      first or second cycle of oxaliplatin-containing regimen, and would consent to randomization
      to standard antiemetic therapy with or without aprepitant.

      III. To obtain preliminary data on the safety and efficacy of aprepitant, in combination with
      dolasetron (dolasetron mesylate) and dexamethasone, in patients receiving
      oxaliplatin-containing regimen.

      IV. To report on medication compliance with antiemetic medications (dexamethasone and
      aprepitant or placebo) scheduled to be taken at home on days 2 and 3 for all randomized
      patients (day 1 = day of treatment).

      OUTLINE: Patients receive standard antiemetics comprising dolasetron mesylate orally (PO) or
      intravenously (IV) and dexamethasone PO or IV during course 1 of oxaliplatin-containing
      chemotherapy. Patients experiencing any grade 1-4 nausea and vomiting* are randomized to 1 of
      2 treatment arms.

      ARM I: Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant
      PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after
      chemotherapy begins during course 2-3.

      ARM II: Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1
      day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after
      chemotherapy begins during courses 2-3.

      In both arms, treatment continues in the absence of unacceptable toxicity.

      NOTE: * Patients not developing nausea and vomiting until the second course of treatment are
      also randomized during courses 3 and 4 of chemotherapy.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient accrual
  </why_stopped>
  <start_date type="Actual">April 19, 2006</start_date>
  <completion_date type="Actual">April 1, 2010</completion_date>
  <primary_completion_date type="Actual">April 1, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with complete response, defined as no emesis and no use of rescue medication</measure>
    <time_frame>Within the first 24 hours of treatment (day 1)</time_frame>
    <description>We will summarize the incidence, severity and time of onset of all nausea and vomiting experienced by all patients who received any oxaliplatin. The complete response rates in both arms will be calculated with 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who agreed to be randomized out of all patients who qualify for randomization</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Malignant Digestive System Neoplasm</condition>
  <condition>Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Arm I (aprepitant, dolasetron mesylate, dexamethasone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo, dolasetron mesylate, dexamethasone)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (aprepitant, dolasetron mesylate, dexamethasone)</arm_group_label>
    <other_name>Emend</other_name>
    <other_name>L-754030</other_name>
    <other_name>MK-0869</other_name>
    <other_name>ONO-7436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm I (aprepitant, dolasetron mesylate, dexamethasone)</arm_group_label>
    <arm_group_label>Arm II (placebo, dolasetron mesylate, dexamethasone)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolasetron Mesylate</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm I (aprepitant, dolasetron mesylate, dexamethasone)</arm_group_label>
    <arm_group_label>Arm II (placebo, dolasetron mesylate, dexamethasone)</arm_group_label>
    <other_name>Anzemet</other_name>
    <other_name>MDL 73,147EF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo, dolasetron mesylate, dexamethasone)</arm_group_label>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have a diagnosis of GI malignancy and who are scheduled to receive their
             initial treatment with an oxaliplatin-containing regimen in combination with
             5-fluorouracil; these include combinations such as fluorouracil, oxaliplatin, and
             leucovorin calcium (FOLFOX), FOLFOX + bevacizumab, FOLFOX + cetuximab

          -  Standard antiemetic therapy with initial treatment must include the dolasetron and
             dexamethasone; the minimum adequate doses include either:

               -  Dolasetron (Anzemet) 100mg PO/IV or 1.8mg/kg IV AND

               -  Dexamethasone (Decadron) 10mg PO/IV

          -  Patient must agree, as part of the informed consent, to keep a journal of the episodes
             of nausea, vomiting, retching, and amount of rescue medications used on days 1 to 5
             (day 1 = day of treatment)

          -  Signed informed consent

        Exclusion Criteria:

          -  Allergy or intolerance to dolasetron and dexamethasone

          -  Use of another antiemetic agent (5HT3 antagonists, phenothiazines, butyrophenones,
             cannabinoids, metoclopramide, or corticosteroids) within 72 hours of day 1 of the
             study

          -  An episode of vomiting or retching within 24 hours before the start of the initial
             treatment with oxaliplatin-containing regimen

          -  Severe concurrent illness other than neoplasia

          -  Gastrointestinal obstruction or an active peptic ulcer

          -  Radiation therapy to the abdomen or pelvis within 1 week before or after day 1 of the
             study

          -  Absolute neutrophil count of less than 1.5 x 10^9/L (unless physician approves to
             proceed with chemotherapy) or

          -  Platelets less than 100 x 109/L (unless physician approves to proceed with
             chemotherapy)

          -  Total bilirubin &gt; 2 x upper limits of normal

          -  Patients who are pregnant or breast feeding

          -  Patients who are non-English speaking

          -  Patients with cancer-induced nausea and vomiting grade 1 or greater using the Common
             Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty Chan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Dolasetron</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

